Results BPD patients showed higher levels of AN compared to the control group ( η 2 = 0.04), though this difference was only marginally significant ( p = 0.050).
Excerpts
borderline significancep = 0.05
CBHL reported statistically significantly greater levels of fatigue than CNH in the General ( p = 0.031), and borderline significance for Cognitive ( p = 0.05), domains of fatigue.
ActiGraph assessed MVPA also increased significantly (MVPA: B = 44.60, p = .006), whereas the increase in ActiGraph assessed days ≥30 min PA was borderline significant (B = 0.38, p = .05).
Prevalence of diseases A total of 3,493 chronic diseases were recorded in the population, corresponding to 4.6 diseases per LLI (4.8 in men and 4.5 in women, p < 0.05); there was a decreasing trend with age, from 4.7 in those under 98 vs. 3.3 in those over 100 ( p < 0.05).
For Audencel patients, a similar trend was visible; however, it did not reach statistical significance ( p = 0.05, Figure 4 ).
For RS, the omnibus test indicated message condition was marginally significant on perceived absolute ENDS risk, F (2, 192) = 3.02, p = 0.05, η p 2 = 0.03.
However, at the joint level, although the percentage of positive crystal deposition in US was higher than that in DECT, the difference did not reach statistical significance ( P = .05). 3.6 Agreement between US and DECT in detecting crystal deposition At the patient level, the consistency of detecting crystal deposition between US and DECT was poor (κ = .24, P = .03).
The average PSA level in patients who were referred for staging of high risk disease was 29.9 ng/mL compared to 14.8 ng/mL in patients with biochemical failure ( p = 0.05, borderline significant).
showed a trendp < 0.05
A comparison of overall fever severity for each treatment group ( Table 3 ) showed a trend towards reduced fever duration and severity (fever-hours) in both treatment groups (p < 0.05).
rs6783836 at ST6GAL1 was associated with HFS in patients treated with XELOX (OR = 3.1, 95% CI = 2.1‐4.6, P = 4.3 × 10 −8 ) and was borderline significant in patients receiving capecitabine from QUASAR2, but with an opposite allele effect (OR = 0.66, 95% CI = 0.42‐1.03, P = .05).
MUC16 expression in pre and post-treatment groups using both drugs (methotrexate and cisplatin) was up-regulated and displayed an increasing trend in the placebo (4.31–5.11%), AF(D)NMs (6.13–6.36%) and IV-drug groups (7.67–8.14%) ( p < 0.05), whilst in the NMs (D) group, MUC16 expression was down-regulated (2.67–3.3%) ( Figure 11 ).
showed a trendp > 0.05
Effects of RP-GABA on growth-related measures under different THI conditions As shown in Supplementary Figure S2 , compared with the control group, RP-GABA supplementation showed a trend toward increased body weight under THI 45, THI 63, and THI 28; however, the differences between groups within each THI condition were not significant ( p > 0.05).
Student’s t -test and two-way ANOVA with post hoc Tukey tests were used to test whether there were differences among treatments after verifying normality (Shapiro test) and homogeneity of variances, with p < 0.01 considered highly significant and p < 0.05 considered significant, both annotated with uppercase and lowercase letters and asterisks.
These differences approached the level of significance when compared with the median values of HS (p = 0.05 and p = 0.04, respectively), but were significantly lower than the value seen in PC patients (p < 0.0001).
For these sites, we thus see strongest evidence that methylation level correlates with educational attainment beyond effects of own smoking behaviour; however, we note that when taking all 58 top sites, effect sizes in never-smokers were strongly correlated with effect sizes in the entire population (r = 0.83), were in the same direction at 57 sites, and were at least nominally significant in never-smokers ( p < 0.05) at 27 sites (Fig. 2b ).
approached significancep ≤ 0.05
The p -value for this comparison was 0.089, indicating that the difference in readmission rates between the two groups approached significance but did not reach conventional thresholds ( p ≤ 0.05).
There was a clear trend of an increase in iron deposition in the liver tissues with increased fibrosis, which became significant at stages 3 and 4 (Figure 4A -F; P < 0.05).
The only nominally significant ( p < 0.05) difference among the randomization groups was for height, which was highest in the metformin group.
Moreover, there was a markedly significant decrease in the WM/RM errors in the mixed groups ( p < 0.05) in the M100 treatment group compared with the negative group ( Figure 4 B,C).
HIV-exposed infants whose mothers tested HIV-negative or were not tested during pregnancy or not taking ART during pregnancy were at increased risk of MTCT, as was starting infant antiretroviral prophylaxis after 72 h and incomplete antiretroviral treatment/prophylaxis (lack of anitretrovirals in either mother or baby or both), however these variables did not reach statistical significance ( p < 0.05).
Differentially methylation CpG sites The epigenome-wide differential methylation analysis revealed 26982 CpG sites that differed between obese and lean individuals with nominally significant p-values (p ≤ 0.05).
Single-trial analyses revealed similar patterns, with a significant leftward shift in change-group start times and no reliable shift in the no-change group, although the difference between groups was only marginally significant in this case [Change group: M = −33% ± 5% SEM, t (8) = −3.27, p<0.05; No-change group: M = −4% ± 11% SEM, t (8) = −0.34, p>0.05; Change vs.
borderline significanceP = 0.05
Three of these studies found significant differences ( P < 0.05), 17 , 53 , 60 and another 1 of these found borderline significance ( P = 0.05). 52 Five 15 , 17 , 53 , 59 , 60 of 7 studies 15 , 17 , 39 , 52 , 53 , 59 , 60 found that food-insecure women had lower protein intake than food-secure women (range, −2% to −7%).
Of 912 total comparisons, 207 were nominally significant (p < 0.05), 74 survived per-family FDR at q < 0.05, and 147 at q < 0.10. 2.4.
Notably, there was a strong trend for correlation with low PLT count as compared to patients without PL (P = 0.05).